Skip to main content

Hyperhidrosis

20
Pipeline Programs
8
Companies
20
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
8
0
5
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

8 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
5 programs
1
1
2
Botulinum Toxin Type APhase 41 trial
Botulinum Toxin Type APhase 41 trial
Botulinum Toxin Type APhase 31 trial
VehiclePhase 21 trial
botulinum toxin Type AN/A1 trial
Active Trials
NCT02043145Completed727Est. Apr 2012
NCT02479139Completed145Est. Feb 2016
NCT00168402Completed193Est. Oct 2005
+2 more trials
Alliance Pharmaceuticals
1 program
1
terazosinPhase 41 trial
Active Trials
NCT00449683Completed23Est. Aug 2013
Journey Medical
Journey MedicalAZ - Scottsdale
5 programs
2
3
Glycopyrronium Topical WipesPhase 31 trial
glycopyrronium Topical WipesPhase 31 trial
glycopyrronium Topical WipesPhase 31 trial
Dose 1 of glycopyrrolate, 2.0% QDPhase 21 trial
glycopyrrolate, 1.0%Phase 21 trial
Active Trials
NCT02129660Completed105Est. Jan 2015
NCT02016885Completed198Est. Sep 2014
NCT02553798Completed564Est. Dec 2016
+2 more trials
ViiV Healthcare
ViiV HealthcareNC - Durham
4 programs
1
2
1
GSK1358820Phase 3
UmeclidiniumPhase 2
UmeclidiniumPhase 2
[14C]Umeclidinium 18.5 mgPhase 1
Botanix Pharmaceuticals
Botanix PharmaceuticalsAustralia - West Perth
5 programs
1
3
BBI-4000 Gel, 5%Phase 21 trial
BBI-4000 gel, 5%Phase 21 trial
BBI-4000, 15%Phase 21 trial
BBI-4000Phase 11 trial
gravimetricN/A1 trial
Active Trials
NCT02552199Completed28Est. Oct 2015
NCT02058264Completed18Est. Sep 2014
NCT02336503Completed189Est. Nov 2015
+2 more trials
Utah Medical
Utah MedicalIreland - Dublin
2 programs
2
Aluminum Chloride 20%Phase 11 trial
Botulinum Toxin Type APhase 11 trial
Active Trials
NCT03416348Completed95Est. Feb 2022
NCT03236012Completed25Est. Feb 2022
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Oxybutynin 3% gelN/A1 trial
Active Trials
NCT02633371Completed10Est. May 2017
GSK
GSKLONDON, United Kingdom
1 program
UmeclidiniumPHASE_21 trial
Active Trials
NCT02673619Completed58Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance Pharmaceuticalsterazosin
AbbVieBotulinum Toxin Type A
AbbVieBotulinum Toxin Type A
Journey Medicalglycopyrronium Topical Wipes
Journey MedicalGlycopyrronium Topical Wipes
Journey Medicalglycopyrronium Topical Wipes
AbbVieBotulinum Toxin Type A
Botanix PharmaceuticalsBBI-4000 gel, 5%
Botanix PharmaceuticalsBBI-4000, 15%
GSKUmeclidinium
AbbVieVehicle
Botanix PharmaceuticalsBBI-4000 Gel, 5%
Journey MedicalDose 1 of glycopyrrolate, 2.0% QD
Journey Medicalglycopyrrolate, 1.0%
Utah MedicalBotulinum Toxin Type A

Showing 15 of 20 trials with date data

Clinical Trials (20)

Total enrollment: 3,920 patients across 20 trials

NCT00449683Alliance Pharmaceuticalsterazosin

Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Start: Mar 2007Est. completion: Aug 201323 patients
Phase 4Completed
NCT00168415AbbVieBotulinum Toxin Type A

A Study Using Botulinum Toxin Type A in Adolescents With Axillary Hyperhidrosis

Start: Aug 2005Est. completion: Jun 2007144 patients
Phase 4Completed
NCT00168480AbbVieBotulinum Toxin Type A

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Start: Nov 2003Est. completion: Apr 2007424 patients
Phase 4Completed
NCT02530294Journey Medicalglycopyrronium Topical Wipes

Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis

Start: Aug 2015Est. completion: Apr 2016353 patients
Phase 3Completed
NCT02553798Journey MedicalGlycopyrronium Topical Wipes

Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Start: Aug 2015Est. completion: Dec 2016564 patients
Phase 3Completed
NCT02530281Journey Medicalglycopyrronium Topical Wipes

Study of Glycopyrronium in Axillary Hyperhydrosis

Start: Jul 2015Est. completion: Mar 2016344 patients
Phase 3Completed
NCT00168402AbbVieBotulinum Toxin Type A

A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis

Start: Feb 2002Est. completion: Oct 2005193 patients
Phase 3Completed
NCT03024255Botanix PharmaceuticalsBBI-4000 gel, 5%

A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Start: Dec 2016Est. completion: Sep 2017227 patients
Phase 2Completed
NCT02682238Botanix PharmaceuticalsBBI-4000, 15%

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis

Start: Mar 2016Est. completion: Oct 201650 patients
Phase 2Completed
NCT02673619GSKUmeclidinium

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

Start: Mar 2016Est. completion: Dec 201658 patients
Phase 2Completed
NCT02479139AbbVieVehicle

Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis

Start: Jun 2015Est. completion: Feb 2016145 patients
Phase 2Completed
NCT02336503Botanix PharmaceuticalsBBI-4000 Gel, 5%

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Start: Mar 2015Est. completion: Nov 2015189 patients
Phase 2Completed
NCT02129660Journey MedicalDose 1 of glycopyrrolate, 2.0% QD

Comparator Study of the Effect of Glycopyrrolate and Glycopyrronium in Subjects With Axillary Hyperhidrosis

Start: Apr 2014Est. completion: Jan 2015105 patients
Phase 2Completed
NCT02016885Journey Medicalglycopyrrolate, 1.0%

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

Start: Nov 2013Est. completion: Sep 2014198 patients
Phase 2Completed
NCT03236012Utah MedicalBotulinum Toxin Type A

Hyperhidrosis in Patients With Amputations-Botox

Start: Jan 2019Est. completion: Feb 202225 patients
Phase 1Completed
NCT03416348Utah MedicalAluminum Chloride 20%

Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2

Start: May 2018Est. completion: Feb 202295 patients
Phase 1Completed
NCT02058264Botanix PharmaceuticalsBBI-4000

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Start: Feb 2014Est. completion: Sep 201418 patients
Phase 1Completed
NCT02633371Colorado TherapeuticsOxybutynin 3% gel

A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults

Start: Feb 2016Est. completion: May 201710 patients
N/ACompleted
NCT02552199Botanix Pharmaceuticalsgravimetric

A Non-Interventional Study To Assess Sweating

Start: Sep 2015Est. completion: Oct 201528 patients
N/ACompleted
NCT02043145AbbViebotulinum toxin Type A

Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea

Start: Jul 2008Est. completion: Apr 2012727 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.